Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy

Journal of Urology

Volumn 169, Issue 2, 2003, Pages 721-723

  Lynn, Naing N K ^a   Howe, Miles C ^a,b   Hale, Richard J ^a   Collins, Gerald N ^a   O'Reilly, Patrick H ^a  

^a STEPPING HILL HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bladder; Carcinoma, transitional cell; Metallothionein; Mitomycin

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; METALLOTHIONEIN; MITOMYCIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER DISEASE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URINARY TRACT CARCINOMA;

EID: 0037305843     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64001-3     Document Type: Article

References (20)

1. Fuse, H., Sakai, T., Kimura, H. and Katayama, T.: Recurrence of superficial bladder tumours after transurethral resection. Int Urol Nephrol, 24: 617, 1992
2. McCluggage, W. G., Maxwell, P., Hamilton, P. W. and Jasani, B.: High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology, 34: 51, 1999
3. Kagi, J. H., Kojima, Y., Kissling, M. M. and Lerch, K.: Metallothionein: an exceptional metal thiolate protein. Ciba Found Symp, 72: 223, 1979
4. Kojima, Y., Berger, C., Vallee, B. L. and Kagi, J. H.: Amino-acid sequence of equine renal metallothionein-1B. Proc Natl Acad Sci USA, 73: 3413, 1976
5. Cherian, M. G., Howell, S. B., Imura, N., Klaassen, C. D., Koropatnick, J., Lazo, J. S. et al: Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol, 126: 1, 1994
6. Bier, B., Douglas-Jones, A., Totsch, M., Dockhorn-Dworniczak, B., Bocker, W., Jasani, B. et al: Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions. Breast Cancer Res Treat, 30: 213, 1994
7. Jasani, B. and Schmid, K. W.: Significance of metallothionein overexpression in human tumours. Histopathology, 31: 211, 1997
8. Masters, B. A., Quaife, C. J., Erickson, J. C., Kelly, E. J., Froelick, G. J., Zambrowicz, B. P. et al: Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles. J Neurosci, 14: 5844, 1994
9. Quaife, C. J., Findley, S. D., Erickson, J. C., Froelick, G. J., Kelly, E. J., Zambrowicz, B. P. et al: Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry, 33: 7250, 1994
10. Zeng, J., Heuchel, R., Schaffner, W. and Kagi, J. H.: Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc finger containing factor Sp1. FEBS Lett, 279: 310, 1991
11. Goulding, H., Jasani, B., Pereira, H., Reid, A., Galea, M., Bell, J. A. et al: Metallothionein expression in human breast cancer. Br J Cancer, 72: 968, 1995
12. Ioachim, E. E., Goussia, A. C., Agnantis, N. J., Machera, M., Tsianos, E. V. and Kappas, A. M.: Prognostic evaluation of metallothionein expression in human colorectal neoplasms. J Clin Pathol, 52: 876, 1999
13. Chin, J. L., Banerjee, D., Kadhim, S. A., Kontozoglou, T. E., Chauvin, P. J. and Cherian, M. G.: Metallothionein in testicular germ cell tumors and drug resistance. Clinical correlation. Cancer, 72: 3029, 1993
14. Bahnson, R. R., Becich, M., Ernstoff, M. S., Sandlow, J., Cohen, M. B. and Williams, R. D.: Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol, 152: 2272, 1994
15. Siu, L. L., Banerjee, D., Khurana, R. J., Pan, X., Pflueger, R., Tannock, I. F. et al: The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res, 4: 559, 1998
16. Singh, S. V., Xu, B. H., Jani, J. P., Emerson, E. O., Backes, M. G., Rihn, C. et al: Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line. Int J Cancer, 61: 431, 1995
17. Saika, T., Tsushima, T., Ochi, J., Akebi, N., Nasu, Y., Matsumura, Y. et al: Over-expression of metallothionein and drug-resistance in bladder cancer. Int J Urol, 1: 135, 1994
18. Sharma, M.: Interaction of mitomycin C with thiol groups of peptides and proteins. Diss Abstr Int B, 54: 1949, 1993
19. Saika, T., Tsushima, T., Nasu, Y., Akebi, N., Noda, M., Kobashi, K. et al: Histopathological study of metallothionein in bladder cancer and renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi, 83: 636, 1992
20. Bahnson, R. R., Banner, B. F., Ernstoff, M. S., Lazo, J. S., Cherian, M. G., Banerjee, D. et al: Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder. J Urol, 146: 1518, 1991